SHUKLA SANJAY (President and CEO) purchased 24.5% of their position (10K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $21.4K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 11/21/2022ACC: 0001209191-22-058295
Officer· President and CEO
Since Feb 2019
+10K
Net shares
Net buyer
$21.4K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
10K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+10K
Price / share
$2.14
Trade value
$21.41K
% of position
24.5%
11/21/2022
40.80K→50.80K
Total
Net shares
+10K
Net value
$21.41K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/21/2022 | P · Purchase | +10K | $2.14 | $21.41K | 24.5% | 40.80K | 50.80K |
| Total | +10K | $21.41K | ||||||
Derivative Transactions0
No derivative transactions reported